Amgen (AMGN) Enterprise Value (2009 - 2026)
Amgen's quarterly Enterprise Value came in at -$12.0 billion in Q1 2026, down 36.64% year-on-year from -$19.0 billion in Q1 2025, and down 31.87% quarter-over-quarter from -$9.1 billion in Q4 2025.
Amgen has reported Enterprise Value for 18 years, with the latest figure at -$12.0 billion in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 36.64% year-over-year to -$12.0 billion; the trailing twelve-month figure through Mar 2026 stood at -$12.0 billion (down 36.64% YoY), and the FY2025 full-year result was -$9.1 billion, up 23.75% from the prior year.
- Enterprise Value for Q1 2026 stood at -$12.0 billion, down from -$9.1 billion in the prior quarter.
- The five-year high for Enterprise Value was -$6.5 billion in Q1 2022, with the low at -$34.7 billion in Q3 2023.
- Average Enterprise Value over 5 years is -$13.7 billion, with a median of -$9.4 billion recorded in 2025.
- Year-over-year, Enterprise Value slumped 382.29% in 2023 and jumped 74.06% in 2024.
- Tracing AMGN's Enterprise Value over 5 years: stood at -$9.3 billion in 2022, then dropped by 17.61% to -$10.9 billion in 2023, then dropped by 9.4% to -$12.0 billion in 2024, then rose by 23.75% to -$9.1 billion in 2025, then slumped by 31.87% to -$12.0 billion in 2026.
- The last three Enterprise Value figures came in at -$12.0 billion (Q1 2026), -$9.1 billion (Q4 2025), and -$9.4 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | -5.28 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | -22.05 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | -9.35 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -5.65 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | -12.04 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | -7.73 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -12.77 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | -10.45 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | -4.68 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.04 Bn |
| Dec 31, 2025 | -9.13 Bn |
| Sep 30, 2025 | -9.45 Bn |
| Jun 30, 2025 | -8.03 Bn |
| Mar 31, 2025 | -8.81 Bn |
| Dec 31, 2024 | -11.97 Bn |
| Sep 30, 2024 | -9.01 Bn |
| Jun 30, 2024 | -9.30 Bn |
| Mar 31, 2024 | -9.71 Bn |
| Dec 31, 2023 | -10.94 Bn |
| Sep 30, 2023 | -34.74 Bn |
| Jun 30, 2023 | -34.25 Bn |
| Mar 31, 2023 | -31.56 Bn |
| Dec 31, 2022 | -9.31 Bn |
| Sep 30, 2022 | -11.48 Bn |
| Jun 30, 2022 | -7.18 Bn |
| Mar 31, 2022 | -6.54 Bn |
| Dec 31, 2021 | -8.04 Bn |
| Sep 30, 2021 | -12.92 Bn |
| Jun 30, 2021 | -8.08 Bn |
| Mar 31, 2021 | -10.57 Bn |
| Dec 31, 2020 | -10.65 Bn |
| Sep 30, 2020 | -12.36 Bn |
| Jun 30, 2020 | -11.42 Bn |
| Mar 31, 2020 | -8.01 Bn |
| Dec 31, 2019 | -8.91 Bn |
| Sep 30, 2019 | -20.85 Bn |
| Jun 30, 2019 | -21.76 Bn |
| Mar 31, 2019 | -26.30 Bn |
| Dec 31, 2018 | -29.30 Bn |
| Sep 30, 2018 | -29.92 Bn |
| Jun 30, 2018 | -29.40 Bn |
| Mar 31, 2018 | -32.17 Bn |
| Dec 31, 2017 | -41.68 Bn |
| Sep 30, 2017 | -41.35 Bn |
| Jun 30, 2017 | -39.23 Bn |
| Mar 31, 2017 | -38.40 Bn |
| Dec 31, 2016 | -38.09 Bn |
| Sep 30, 2016 | -37.98 Bn |
| Jun 30, 2016 | -35.03 Bn |
| Mar 31, 2016 | -34.74 Bn |
| Dec 31, 2015 | -31.38 Bn |
| Sep 30, 2015 | -31.12 Bn |
| Jun 30, 2015 | -29.99 Bn |
| Mar 31, 2015 | -27.12 Bn |
| Dec 31, 2014 | -27.03 Bn |
| Sep 30, 2014 | -28.08 Bn |
| Jun 30, 2014 | -26.19 Bn |
| Mar 31, 2014 | -19.80 Bn |
| Dec 31, 2013 | -19.40 Bn |
| Sep 30, 2013 | -11.16 Bn |
| Jun 30, 2013 | -22.02 Bn |
| Mar 31, 2013 | -21.27 Bn |
| Dec 31, 2012 | -24.06 Bn |
| Sep 30, 2012 | -25.37 Bn |
| Jun 30, 2012 | -5.85 Bn |
| Mar 31, 2012 | -4.21 Bn |
| Dec 31, 2011 | -20.64 Bn |
| Sep 30, 2011 | -22.37 Bn |
| Jun 30, 2011 | -13.21 Bn |
| Mar 31, 2011 | -7.20 Bn |
| Dec 31, 2010 | -17.89 Bn |
| Sep 30, 2010 | -11.62 Bn |
| Jun 30, 2010 | -7.61 Bn |
| Mar 31, 2010 | -5.43 Bn |
| Dec 31, 2009 | -15.30 Bn |
| Sep 30, 2009 | -14.47 Bn |
| Jun 30, 2009 | -10.45 Bn |
| Mar 31, 2009 | -2.78 Bn |